Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Deffered Revenue: 2011-2024

Historic Non-Current Deffered Revenue for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $2.6 million.

  • Niagen Bioscience's Non-Current Deffered Revenue rose 3.68% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 3.68%. This contributed to the annual value of $2.6 million for FY2024, which is 22.11% down from last year.
  • According to the latest figures from FY2024, Niagen Bioscience's Non-Current Deffered Revenue is $2.6 million, which was down 22.11% from $3.3 million recorded in FY2023.
  • Niagen Bioscience's Non-Current Deffered Revenue's 5-year high stood at $4.4 million during FY2020, with a 5-year trough of $2.6 million in FY2024.
  • Over the past 3 years, Niagen Bioscience's median Non-Current Deffered Revenue value was $3.3 million (recorded in 2023), while the average stood at $3.3 million.
  • Per our database at Business Quant, Niagen Bioscience's Non-Current Deffered Revenue grew by 14.67% in 2020 and then fell by 22.11% in 2024.
  • Yearly analysis of 5 years shows Niagen Bioscience's Non-Current Deffered Revenue stood at $4.4 million in 2020, then fell by 2.14% to $4.3 million in 2021, then decreased by 7.96% to $4.0 million in 2022, then declined by 17.23% to $3.3 million in 2023, then decreased by 22.11% to $2.6 million in 2024.